Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Physiological evidence for diversification of IFNα- and IFNβ-mediated response programs in different autoimmune diseases

TD. de Jong, S. Vosslamber, E. Mantel, S. de Ridder, JG. Wesseling, TC. van der Pouw Kraan, C. Leurs, H. Hegen, F. Deisenhammer, J. Killestein, IE. Lundberg, J. Vencovsky, MT. Nurmohamed, D. van Schaardenburg, IE. Bultink, AE. Voskuyl, DM....

. 2016 ; 18 (-) : 49. [pub] 20160217

Language English Country England, Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc17000456

BACKGROUND: Activation of the type I interferon (IFN) response program is described for several autoimmune diseases, including systemic lupus erythematosus (SLE), multiple sclerosis (MS), myositis (IIM) and rheumatoid arthritis (RA). While IFNα contributes to SLE pathology, IFNβ therapy is often beneficial in MS, implying different immunoregulatory roles for these IFNs. This study was aimed to investigate potential diversification of IFNα-and IFNβ-mediated response programs in autoimmune diseases. METHODS: Peripheral blood gene expression of 23 prototypical type I IFN response genes (IRGs) was determined in 54 healthy controls (HCs), 69 SLE (47 test, 22 validation), 149 IFNβ-treated MS (71 test, 78 validation), 160 untreated MS, 78 IIM and 76 RA patients. Patients with a type I IFN signature were selected for analysis. RESULTS: We identified IFNα- and IFNβ-specific response programs (GC-A and GC-B, respectively) in SLE and IFNβ-treated MS patients. Concordantly, the GC-A/GC-B log-ratio was positive for all SLE patients and negative for virtually all IFNβ-treated MS patients, which was confirmed in additional cohorts. Applying this information to other autoimmune diseases, IIM patients displayed positive GC-A/GC-B log-ratios, indicating predominant IFNα activity. The GC-A/GC-B log-ratio in RA was lower and approached zero in part of the patients, implying relative importance of both clusters. Remarkably, GC-A/GC-B log-ratios appeared most heterogeneous in untreated MS; half of the patients displayed GC-A dominance, whereas others showed GC-B dominance or log-ratios near zero. CONCLUSIONS: Our findings show diversification of the type I IFN response in autoimmune diseases, suggesting different pathogenic roles of the type I IFNs.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17000456
003      
CZ-PrNML
005      
20170113104039.0
007      
ta
008      
170103s2016 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s13075-016-0946-9 $2 doi
024    7_
$a 10.1186/s13075-016-0946-9 $2 doi
035    __
$a (PubMed)26882897
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a de Jong, Tamarah D $u Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands. td.dejong@vumc.nl.
245    10
$a Physiological evidence for diversification of IFNα- and IFNβ-mediated response programs in different autoimmune diseases / $c TD. de Jong, S. Vosslamber, E. Mantel, S. de Ridder, JG. Wesseling, TC. van der Pouw Kraan, C. Leurs, H. Hegen, F. Deisenhammer, J. Killestein, IE. Lundberg, J. Vencovsky, MT. Nurmohamed, D. van Schaardenburg, IE. Bultink, AE. Voskuyl, DM. Pegtel, CJ. van der Laken, JW. Bijlsma, CL. Verweij,
520    9_
$a BACKGROUND: Activation of the type I interferon (IFN) response program is described for several autoimmune diseases, including systemic lupus erythematosus (SLE), multiple sclerosis (MS), myositis (IIM) and rheumatoid arthritis (RA). While IFNα contributes to SLE pathology, IFNβ therapy is often beneficial in MS, implying different immunoregulatory roles for these IFNs. This study was aimed to investigate potential diversification of IFNα-and IFNβ-mediated response programs in autoimmune diseases. METHODS: Peripheral blood gene expression of 23 prototypical type I IFN response genes (IRGs) was determined in 54 healthy controls (HCs), 69 SLE (47 test, 22 validation), 149 IFNβ-treated MS (71 test, 78 validation), 160 untreated MS, 78 IIM and 76 RA patients. Patients with a type I IFN signature were selected for analysis. RESULTS: We identified IFNα- and IFNβ-specific response programs (GC-A and GC-B, respectively) in SLE and IFNβ-treated MS patients. Concordantly, the GC-A/GC-B log-ratio was positive for all SLE patients and negative for virtually all IFNβ-treated MS patients, which was confirmed in additional cohorts. Applying this information to other autoimmune diseases, IIM patients displayed positive GC-A/GC-B log-ratios, indicating predominant IFNα activity. The GC-A/GC-B log-ratio in RA was lower and approached zero in part of the patients, implying relative importance of both clusters. Remarkably, GC-A/GC-B log-ratios appeared most heterogeneous in untreated MS; half of the patients displayed GC-A dominance, whereas others showed GC-B dominance or log-ratios near zero. CONCLUSIONS: Our findings show diversification of the type I IFN response in autoimmune diseases, suggesting different pathogenic roles of the type I IFNs.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a autoimunitní nemoci $x krev $x farmakoterapie $x imunologie $7 D001327
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a interferon alfa $x terapeutické užití $7 D016898
650    _2
$a interferon beta $x terapeutické užití $7 D016899
650    _2
$a systémový lupus erythematodes $x krev $x farmakoterapie $x imunologie $7 D008180
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a roztroušená skleróza $x krev $x farmakoterapie $x imunologie $7 D009103
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Vosslamber, Saskia $u Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands. s.vosslamber@vumc.nl.
700    1_
$a Mantel, Elise $u Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands. e.mantel@vumc.nl.
700    1_
$a de Ridder, Sander $u Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands. s.deridder@vumc.nl.
700    1_
$a Wesseling, John G $u Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands. j.g.wesseling@durrercenter.nl.
700    1_
$a van der Pouw Kraan, Tineke C T M $u Department of Molecular Cell Biology and Immunology, VU University Medical Center, Amsterdam, The Netherlands. t.vanderpouwkraan@vumc.nl.
700    1_
$a Leurs, Cyra $u Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands. c.leurs@vumc.nl.
700    1_
$a Hegen, Harald $u Department of Neurology, Innsbruck Medical University, Innsbruck, Austria. harald.hegen@i-med.ac.at.
700    1_
$a Deisenhammer, Florian $u Department of Neurology, Innsbruck Medical University, Innsbruck, Austria. Florian.Deisenhammer@tirol-kliniken.at.
700    1_
$a Killestein, Joep $u Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands. j.killestein@vumc.nl.
700    1_
$a Lundberg, Ingrid E $u Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden. Ingrid.Lundberg@ki.se.
700    1_
$a Vencovsky, Jiri $u Institute of Rheumatology, Prague, Czech Republic. vencovsky@revma.cz.
700    1_
$a Nurmohamed, Mike T $u Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Reade, Amsterdam, The Netherlands. m.nurmohamed@reade.nl.
700    1_
$a van Schaardenburg, Dirkjan $u Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Reade, Amsterdam, The Netherlands. d.v.schaardenburg@reade.nl.
700    1_
$a Bultink, Irene E M $u Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, VUmc, Amsterdam, The Netherlands. IEM.Bultink@vumc.nl.
700    1_
$a Voskuyl, Alexandre E $u Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, VUmc, Amsterdam, The Netherlands. AE.Voskuyl@vumc.nl.
700    1_
$a Pegtel, D Michiel $u Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands. d.pegtel@vumc.nl.
700    1_
$a van der Laken, Conny J $u Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, VUmc, Amsterdam, The Netherlands. J.vanderLaken@vumc.nl.
700    1_
$a Bijlsma, Johannes W J $u Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Reade, Amsterdam, The Netherlands. j.bijlsma@vumc.nl. Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, VUmc, Amsterdam, The Netherlands. j.bijlsma@vumc.nl.
700    1_
$a Verweij, Cornelis L $u Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands. c.verweij@vumc.nl. Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, VUmc, Amsterdam, The Netherlands. c.verweij@vumc.nl.
773    0_
$w MED00007534 $t Arthritis research & therapy $x 1478-6362 $g Roč. 18, č. - (2016), s. 49
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26882897 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170103 $b ABA008
991    __
$a 20170113104139 $b ABA008
999    __
$a ok $b bmc $g 1179596 $s 961023
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 18 $c - $d 49 $e 20160217 $i 1478-6362 $m Arthritis research & therapy $n Arthritis Res Ther $x MED00007534
LZP    __
$a Pubmed-20170103

Find record

Citation metrics

Archiving options